{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:50:07Z","timestamp":1792752607176,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-04213-y","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:46:11Z","timestamp":1755233171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran"],"prefix":"10.1186","volume":"25","author":[{"given":"Nazanin","family":"Ahmad Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azar Dokht","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hashemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Savari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Saki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"4213_CR1","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva, Switzerland: World Health Organization; 2024."},{"issue":"2","key":"4213_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/medicina58020188","volume":"58","author":"J Espinosa-Pereiro","year":"2022","unstructured":"Espinosa-Pereiro J, S\u00e1nchez-Montalv\u00e1 A, Aznar ML, Espiau M. MDR tuberculosis treatment. Medicina (B Aires). 2022;58(2):188.","journal-title":"Medicina (B Aires)"},{"issue":"12","key":"4213_CR3","first-page":"e50222","volume":"15","author":"D Vishwakarma","year":"2023","unstructured":"Vishwakarma D, Gaidhane A, Sahu S, Rathod AS. Multi-drug resistance tuberculosis (MDR-TB) challenges in India: a review. Cureus. 2023;15(12):e50222.","journal-title":"Cureus"},{"issue":"2","key":"4213_CR4","doi-asserted-by":"publisher","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","volume":"48","author":"H Hatami","year":"2022","unstructured":"Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.","journal-title":"J Bras Pneumol"},{"issue":"4","key":"4213_CR5","doi-asserted-by":"publisher","first-page":"e007490","DOI":"10.1136\/bmjgh-2021-007490","volume":"7","author":"C Perrin","year":"2022","unstructured":"Perrin C, Athersuch K, Elder G, Martin M, Alsalhani A. Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study. BMJ Glob Health. 2022;7(4):e007490.","journal-title":"BMJ Glob Health"},{"key":"4213_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2023.05.001","volume":"34","author":"Q An","year":"2023","unstructured":"An Q, Lin R, Yang Q, Wang C, Wang D. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2023;34:214\u201326.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"4213_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","volume":"7","author":"F von Groote-Bidlingmaier","year":"2019","unstructured":"von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of Delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249\u201359.","journal-title":"Lancet Respir Med"},{"key":"4213_CR8","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","volume":"124","author":"MJ Nasiri","year":"2022","unstructured":"Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis. 2022;124:S90\u2013103.","journal-title":"Int J Infect Dis"},{"key":"4213_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jgar.2021.06.007","volume":"26","author":"W He","year":"2021","unstructured":"He W, Liu C, Liu D, Ma A, Song Y, He P, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and Delamanid in China. J Glob Antimicrob Resist. 2021;26:241\u20138.","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"4213_CR10","first-page":"784","volume":"16","author":"WC Gan","year":"2023","unstructured":"Gan WC, Ng HF, Ngeow YF. Mechanisms of linezolid resistance in mycobacteria. Pharm. 2023;16(6):784.","journal-title":"Pharm"},{"key":"4213_CR11","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.2147\/IDR.S429003","volume":"16","author":"E Tong","year":"2023","unstructured":"Tong E, Zhou Y, Liu Z, Zhu Y, Zhang M, Wu K. Bedaquiline resistance and molecular characterization of rifampicin-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Infect Drug Resist. 2023;16:6951\u201363.","journal-title":"Infect Drug Resist"},{"key":"4213_CR12","doi-asserted-by":"publisher","first-page":"717045","DOI":"10.3389\/fmicb.2021.717045","volume":"12","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, et al. Mechanism of action, resistance, synergism, and clinical implications of Delamanid against multidrug-resistant Mycobacterium tuberculosis. Front Microbiol. 2021;12:717045.","journal-title":"Front Microbiol"},{"key":"4213_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jgar.2019.06.013","volume":"19","author":"Y Chandramohan","year":"2019","unstructured":"Chandramohan Y, Padmanaban V, Bethunaickan R, Tripathy S, Swaminathan S, Ranganathan UD. In vitro interaction profiles of the new antitubercular drugs bedaquiline and Delamanid with Moxifloxacin against clinical Mycobacterium tuberculosis isolates. J Glob Antimicrob Resist. 2019;19:348\u201353.","journal-title":"J Glob Antimicrob Resist"},{"key":"4213_CR14","volume-title":"Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. License: CC BY-NC-SA 3.0 IGO","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. License: CC BY-NC-SA 3.0 IGO. Geneva: WHO; 2018. (WHO\/CDS\/TB\/2018.24)."},{"key":"4213_CR15","unstructured":"World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. World Health Organization; 2018."},{"key":"4213_CR16","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. 2022. http:\/\/www.eucast.org"},{"key":"4213_CR17","first-page":"20","volume-title":"CLSI standard document M24-A2","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. In: CLSI standard document M24-A2. 2nd ed. Wayne PA: Clinical and Laboratory Standards Institute; 2011. p. 20\u20135.","edition":"2"},{"issue":"12","key":"4213_CR18","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1128\/JCM.01123-16","volume":"54","author":"K Kaniga","year":"2016","unstructured":"Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, et al. A multilaboratory, multicountry study to determine bedaquiline MIC quality control ranges for phenotypic drug susceptibility testing. J Clin Microbiol. 2016;54(12):2956\u201362.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"4213_CR19","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1007\/s11033-022-07404-2","volume":"49","author":"P Bakhtiyariniya","year":"2022","unstructured":"Bakhtiyariniya P, Khosravi AD, Hashemzadeh M, Savari M. Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran. Mol Biol Rep. 2022;49(7):6135\u201343.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"4213_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06024-8","volume":"21","author":"H Zheng","year":"2021","unstructured":"Zheng H, He W, Jiao W, Xia H, Sun L, Wang S, et al. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and Delamanid in Southwest of China. BMC Infect Dis. 2021;21(1):1\u20136.","journal-title":"BMC Infect Dis"},{"key":"4213_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijid.2020.07.044","volume":"99","author":"J Yang","year":"2020","unstructured":"Yang J, Pang Y, Zhang T, Xian X, Li Y, Wang R, et al. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. Int J Infect Dis. 2020;99:163\u201370.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"4213_CR22","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1128\/AAC.02941-15","volume":"60","author":"S Zhang","year":"2016","unstructured":"Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al.Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother. 2016;60(4):2542\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"4213_CR23","first-page":"15","volume":"38","author":"N Ahmad Khosravi","year":"2024","unstructured":"Ahmad Khosravi N, Sirous M, Khosravi AD, Saki M. A narrative review of bedaquiline and delamanid: new arsenals against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. J Clin Lab Anal. 2024;38:15\u20136.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"4213_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020465","volume":"9","author":"J Kardan-Yamchi","year":"2020","unstructured":"Kardan-Yamchi J, Kazemian H, Battaglia S, Abtahi H, Rahimi Foroushani A, Hamzelou G, et al. Whole genome sequencing results associated with minimum inhibitory concentrations of 14 anti-tuberculosis drugs among rifampicin-resistant isolates of Mycobacterium tuberculosis from Iran. J Clin Med. 2020;9(2): 465.","journal-title":"J Clin Med"},{"key":"4213_CR25","doi-asserted-by":"publisher","first-page":"101437","DOI":"10.1016\/j.nmni.2024.101437","volume":"60\u201361","author":"AH Akbari Aghababa","year":"2024","unstructured":"Akbari Aghababa AH, Nasiri MJ, Pakzad P, Mirsamadi ES. Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in iran: A cross-sectional analysis. New Microb New Infect. 2024;60\u201361:101437.","journal-title":"New Microb New Infect"},{"issue":"3","key":"4213_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/femsre\/fux011","volume":"41","author":"SM Gygli","year":"2017","unstructured":"Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354\u201373.","journal-title":"FEMS Microbiol Rev"},{"issue":"5","key":"4213_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41579-021-00649-x","volume":"20","author":"DGJ Larsson","year":"2022","unstructured":"Larsson DGJ, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20(5):257\u201369.","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"4213_CR28","doi-asserted-by":"publisher","first-page":"e01304","DOI":"10.1128\/JCM.01304-20","volume":"58","author":"S Battaglia","year":"2020","unstructured":"Battaglia S, Spitaleri A, Cabibbe AM, Meehan CJ, Utpatel C, Ismail N, et al. Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naive Mycobacterium tuberculosis clinical strains. J Clin Microbiol. 2020;58(11):e01304-20.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"4213_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","volume":"38","author":"JS Yang","year":"2018","unstructured":"Yang JS, Kim KJ, Choi H, Lee SH. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med. 2018;38(6):563.","journal-title":"Ann Lab Med"},{"issue":"12","key":"4213_CR30","doi-asserted-by":"publisher","first-page":"e0053122","DOI":"10.1128\/aac.00531-22","volume":"66","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shi J, Li L, Wu T, Chu P, Pang Y, et al. Spontaneous mutational patterns and novel mutations for Delamanid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022;66(12):e0053122.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4213_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12941-024-00694-3","volume":"23","author":"N Madadi-Goli","year":"2024","unstructured":"Madadi-Goli N, Ahmadi K, Kamakoli MK, Azizi M, Khanipour S, Dizaji SP, et al. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran. Ann Clin Microbiol Antimicrob. 2024;23(1):36.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"7","key":"4213_CR32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/jac\/dkz150","volume":"74","author":"R Pi","year":"2019","unstructured":"Pi R, Liu Q, Jiang Q, Gao Q. Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS. J Antimicrob Chemother. 2019;74(7):1795\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4213_CR33","doi-asserted-by":"publisher","first-page":"955050","DOI":"10.3389\/fphar.2022.955050","volume":"13","author":"T Azimi","year":"2022","unstructured":"Azimi T, Khoshnood S, Asadi A, Heidary M, Mahmoudi H, Kaviar VH, et al. Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: a systematic review and meta-analysis. Front Pharmacol. 2022;13:955050.","journal-title":"Front Pharmacol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04213-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04213-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:48:21Z","timestamp":1757486901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-04213-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04213-y","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The published version was updated as the author noticed an error in affiliation 2 and that he wanted this to be changed to \"Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran\".","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (No: IR.AJUMS.MEDICINE.REC.1401.062). This investigation was carried out in accordance with the Declaration of Helsinki, and the requisite permission was given to the collection of samples. Written informed consent was obtained from all patients. Moreover, AI-assisted technologies including Quillbot () and Grammarly () were used to improve readability and language of some parts of this work. Applying these technologies was done with human oversight and control and all contents were reviewed and edited carefully. After using this services, the authors take full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"509"}}